Tuesday, January 3, 2017

BRIEF-Tracon Pharmaceuticals receives special protocol assessment agreement from FDA

* Receives special protocol assessment (SPA) agreement from

FDA for phase 3 clinical trial of TRC105 in angiosarcoma

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)